Published in J Womens Health (Larchmt) on June 10, 2011
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Experiences with HIV testing, entry, and engagement in care by HIV-infected women of color, and the need for autonomy, competency, and relatedness. AIDS Patient Care STDS (2013) 1.08
Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS (2014) 0.99
Recruitment and retention of African American and Hispanic girls and women in research. Public Health Nurs (2012) 0.92
Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study. J Womens Health (Larchmt) (2014) 0.91
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
Strategies to Build Trust and Recruit African American and Latino Community Residents for Health Research: A Cohort Study. Clin Transl Sci (2015) 0.85
Recruiting Chinese Americans into cancer screening intervention trials: strategies and outcomes. Clin Trials (2014) 0.84
Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat (2011) 0.83
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS (2013) 0.79
Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res (2013) 0.78
Women in HIV cure research: multilevel interventions to improve sex equity in recruitment. J Virus Erad (2016) 0.75
ResearchTracking: Monitoring gender and ethnic minority recruitment and retention in cancer symptom studies. Cancer Nurs (2013) 0.75
A randomized controlled exercise training trial on insulin sensitivity in African American men: The ARTIIS study: Major category: study design, statistical design, study protocols. Contemp Clin Trials (2015) 0.75
Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials (2017) 0.75
HIV/AIDS: a minority health issue. Med Clin North Am (2005) 1.96
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr (2009) 1.49
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr (2000) 1.45
Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf (2005) 1.35
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials (2007) 1.01
Sex differences in HAART-associated dyslipidaemia. AIDS (2001) 1.00
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis (2006) 2.91
Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2010) 2.25
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr (2002) 1.97
Comet 81P/Wild 2 under a microscope. Science (2006) 1.83
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr (2003) 1.77
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis (2005) 1.66
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS (2011) 1.30
Screening and assessment of coronary heart disease in HIV-infected patients. Circulation (2008) 1.29
Performance of different mono- and multiplex nucleic acid amplification tests on a multipathogen external quality assessment panel. J Clin Microbiol (2011) 1.27
HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS (2007) 1.25
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med (2012) 1.15
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS (2011) 1.10
Incidence and prevalence of dementia in elderly adults with mental retardation without down syndrome. Am J Ment Retard (2004) 1.07
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS (2008) 1.07
Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard (2004) 1.05
Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS (2008) 1.03
Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther (2011) 1.02
Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics (2012) 1.02
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Res Treat (2012) 1.00
HIV health care services for Mexican migrants. J Acquir Immune Defic Syndr (2004) 1.00
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther (2010) 0.97
The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis (2004) 0.97
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr (2010) 0.96
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther (2003) 0.96
The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care (2012) 0.96
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol (2008) 0.94
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother (2014) 0.94
Bacterial Signal Transduction by Cyclic Di-GMP and Other Nucleotide Second Messengers. J Bacteriol (2016) 0.93
Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health (2011) 0.93
Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther (2011) 0.90
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother (2010) 0.90
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials (2011) 0.89
Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS (2009) 0.88
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic) (2004) 0.88
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS Res Hum Retroviruses (2012) 0.87
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clin Infect Dis (2003) 0.87
Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache (2002) 0.86
Stanford-Binet & WAIS IQ Differences and Their Implications for Adults with Intellectual Disability (aka Mental Retardation). Intelligence (2010) 0.85
Prolonged shedding of rhinovirus and re-infection in adults with respiratory tract illness. Eur Respir J (2014) 0.85
Pregnancy rates and predictors in women with HIV/AIDS in Rio de Janeiro, Southeastern Brazil. Rev Saude Publica (2011) 0.84
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. J Acquir Immune Defic Syndr (2015) 0.83
Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat (2011) 0.83
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr (2016) 0.83
Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS (2003) 0.82
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS (2011) 0.82
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials (2008) 0.81
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr (2014) 0.80
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. J Clin Immunol (2011) 0.80
Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDS (2003) 0.80
Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia. J Policy Pract Intellect Disabil (2013) 0.80
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc (2012) 0.80
A novel codon insert in protease of clade B HIV type 1. AIDS Res Hum Retroviruses (2009) 0.80
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS (2014) 0.79
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS (2013) 0.79
Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials (2010) 0.79
Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache (2003) 0.79
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis (2014) 0.78
Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother (2009) 0.78
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol (2004) 0.77
Report from the 14th Retrovirus Conference. Metabolic complications: lipoatrophy, lipohypertrophy, and cardiovascular risk. AIDS Clin Care (2007) 0.77
Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. Curr HIV Res (2013) 0.76
Cardiovascular risk factors and antiretroviral therapy. N Engl J Med (2003) 0.76
Report from the 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Treatment for patients with central fat accumulation. J Watch AIDS Clin Care (2010) 0.75
Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network. AIDS Res Treat (2013) 0.75
One-on-one with Dawn Averitt Bridge. Wife, mother, and advocate for HIV-positive women. Interview by Jeff Berry. Posit Aware (2009) 0.75
From laboratory bench to living room: one woman's perspective on life with HIV. Am J Reprod Immunol (2011) 0.75
Report from the 7th International Lipodystrophy Meeting. AIDS Clin Care (2006) 0.75
Report on the XIV International AIDS Conference. AIDS Clin Care (2002) 0.75
Report from the 13th retrovirus conference. Metabolic complications and cardiovascular disease. AIDS Clin Care (2006) 0.75
Report from the Tenth Retrovirus Conference. Metabolic complications. AIDS Clin Care (2003) 0.75
Report from the 11th conference on retroviruses and opportunistic infections. Metabolic complications. AIDS Clin Care (2004) 0.75
Report from the 11th conference on retroviruses and opportunistic infections. Neurology of HIV. AIDS Clin Care (2004) 0.75
Top stories of 2004. HAART and the heart. AIDS Clin Care (2005) 0.75
Meeting notes from the 3rd IAS Conference. HIV treatment and risk for metabolic complications. AIDS Clin Care (2005) 0.75
Meeting report from the XV International AIDS Conference. Metabolic complications. AIDS Clin Care (2004) 0.75